1. Pemphigus-like hypereosinophilic syndrome with FIP1L1-PDGFRA fusion gene: A challenging and uncommon clinical presentation.
- Author
-
Curto-Barredo L, Segura S, Ishii N, Hashimoto T, Mascaró JM Jr, Espinet B, Besses C, and Pujol RM
- Subjects
- Diagnosis, Differential, Humans, Hypereosinophilic Syndrome drug therapy, Hypereosinophilic Syndrome genetics, Hypereosinophilic Syndrome immunology, Imatinib Mesylate pharmacology, In Situ Hybridization, Fluorescence, Male, Middle Aged, Mouth Mucosa immunology, Mouth Mucosa pathology, Oncogene Proteins, Fusion antagonists & inhibitors, Receptor, Platelet-Derived Growth Factor alpha antagonists & inhibitors, Severity of Illness Index, Stomatitis drug therapy, Stomatitis genetics, Stomatitis immunology, Treatment Outcome, mRNA Cleavage and Polyadenylation Factors antagonists & inhibitors, Hypereosinophilic Syndrome diagnosis, Imatinib Mesylate therapeutic use, Oncogene Proteins, Fusion genetics, Pemphigus diagnosis, Receptor, Platelet-Derived Growth Factor alpha genetics, Stomatitis diagnosis, mRNA Cleavage and Polyadenylation Factors genetics
- Abstract
Hypereosinophilic syndrome (HES) is often associated with cutaneous manifestations, mostly pruritic lesions, urticaria and angioedema. Mucosal lesions are rarely seen in HES but, when present, are usually the first manifestation of the disease. The clinical presentation may be heterogeneous, including erosions, aphthae or ulcers, and can be easily confused with other mucocutaneous disorders. Here, we present the case of a 64-year-old man with severe chronic erosive oral mucositis simulating pemphigus in which the finding of persistent eosinophilia and elevation of B
12 vitamin serum levels raised the suspicion of HES. The FIP1L1-PDGFRA fusion gene (4q12) was detected by fluorescence in situ hybridization and the patient was treated with imatinib mesylate with complete response of the disease., (© 2019 Japanese Dermatological Association.)- Published
- 2019
- Full Text
- View/download PDF